Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy
- 11 January 2016
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 53 (1) , 174-181
Abstract
Detecting persistent/recurrent disease of medullary thyroid carcinoma (MTC) is important. The tumor-node-metastasis (TNM) staging system is useful for predicting disease-specific mortality, but is a static system and does not include postoperative serum calcitonin levels. We have focused on the clinical usefulness of dynamic risk stratification (DRS) using the best response to the initial therapy in MTC patients. A total of 120 MTC patients were classified into three DRS groups based on their responses to initial therapy. Clinical outcomes were assessed according to TNM staging and DRS. In the DRS, 70, 23 and 7 % of the MTC patients were classified into excellent, biochemical incomplete, or structural incomplete response groups, respectively. On TNM staging, 37, 16, 13 and 35 % of patients were stages I–IV, respectively. There were significant differences in survivals according to TNM staging (p = 0.03) and DRS (p = 0.005). During the median follow-up of 6.2 years, 75 patients (63 %) demonstrated no evidence of disease (NED). About 60 and 17 % of patients in stages III and IV were NED, respectively. DRS predicted NED better than TNM staging according to the proportion of variance explained (PVE) (49.1 vs. 28.7 %, respectively). At the final follow-up, 88, 4 and 0 % of patients in excellent, biochemical incomplete, and structural incomplete response groups attained NED, respectively. DRS based on the best response to the initial therapy can provide useful prognostic information in addition to initial TNM staging for predicting of mortality, as well as the likelihood of NED in MTC patients.Keywords
Funding Information
- Bumsuck Academic Research Fund
This publication has 24 references indexed in Scilit:
- Risk stratification in medullary thyroid cancer: Moving beyond static anatomic stagingOral Oncology, 2013
- Advances in the follow-up of differentiated or medullary thyroid cancerNature Reviews Endocrinology, 2012
- Clinicopathological Characteristics and Prognostic Factors of Medullary Thyroid CarcinomaEndocrinology and Metabolism, 2010
- The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CTEuropean Radiology, 2009
- Long‐term prognosis of medullary thyroid carcinomaClinical Endocrinology, 2008
- Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patientsEuropean Journal of Surgical Oncology, 2007
- Prognosis of medullary thyroid carcinomaCancer, 2006
- Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patientsClinical Endocrinology, 1998
- Prognostic factors for thyroid carcinomaCancer, 1997
- Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.The Journal of Clinical Endocrinology & Metabolism, 1994